Skip to main content

Table 4 The effect of L-NMMA on components of the renin-angiotensin system and plasma levels of sodium and potassium after six weeks of paricalcitol treatment (n = 26)

From: Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial

  Baseline 60 min 120 min P Within P Between
PRC (pg/ml)
Placebo 10.4 [6.1;23.6] 10.1 [6.1;18.8] 8.2 [6.8;17.1] 0.02 <0.01 0.31
Paricalcitol 10.9 [6.4;25.2] 8.4 [5.7;18.3] 8.9 [6.5;19.3]  
p-AngII (pg/ml)
Placebo 5.0 [8.0;12.0] 6.5 [4.0;12.0] 7.5 [5.0;9.0] 0.01 0.17
Paricalcitol 8.0 [5.0;15.0] 7.0 [5.0;12.0] 8.0 [4.5;12.0] <0.01
p-Aldo (pmol/l)
Placebo 287 [152;607] 376 [180;663] 302 [161;520] <0.01 0.24
Paricalcitol 335 [187;619] 346 [200;742] 282 [165;590] <0.01
p-K (mmol/l)
Placebo 4.0 [3.7;4.4] 3.9 [3.7;4.4] 3.9 [3.7;4.4] 0.96 0.19
Paricalcitol 3.8 [3.6;4.2]* 3.7 [3.6;4.2] 3.8 [3.6;4.2] 0.80
p-Na (mmol/l)
Placebo 138 [136;140] 138 [136;138] 137 [135;140] 0.76 0.33
Paricalcitol 138 [136;140] 138 [136;140] 138 [136;140] 0.33
p-BNP (pmol/l)
Placebo 8.1[4.4;19.5] - -  
Paricalcitol 7.5[4.8;14.3] - -  
p-AVP (pg/ml)
Placebo 0.5 [0.4;0.7] - -  
Paricalcitol 0.5 [0.4;0.7] - -  
  1. Values are medians with 25 and 75 percentiles in brackets. L-NMMA, NG-monomethyl-L-arginine; PRC, plasma renin concentration; AngII, angiotensin II; Aldo, aldosterone; K, potassium; Na, sodium; BNP, brain natriuretic peptide; AVP, vasopressin. L-NMMA infusion was sustained for 60 minutes. Pwithin represents the probability of an effect of NOS inhibition after each treatment assessed by Friedman’s ANOVA. Pbetween represents the probability that paricalcitol alters the response to L-NMMA assessed by a general linear model for repeated measures with treatment as factor.
  2. * = p < 0.05 vs. placebo at baseline.